Combination Drug Development Incentive Act of 2015
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jan 20, 2015)
Combination Drug Development Incentive Act of 2015
This bill amends the Federal Food, Drug, and Cosmetic Act to provide a five-year marketing exclusivity period to a new drug approved by the Food and Drug Administration that is a novel combination of active ingredients. The application for the combination drug must contain reports of new clinical investigations that are essential to approval and were conducted or sponsored by the applicant. Currently, a new drug that includes an active ingredient that has already been approved is provided a three-year marketing exclusivity period.
What just happenedJan 23, 2015
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJan 20, 2015
- Jan 23, 2015Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jan 20, 2015IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jan 20, 2015IntroReferralIntro-H
Introduced in House
- Jan 20, 2015IntroReferral1000
Introduced in House